 Fabs are a common form-factor for monoclonal antibodies designated for therapeutic use.The Fab abciximab, which inhibits blood clotting, works by disabling Glycoprotein IIb/IIIa fount on platelets.Ranibizumab, a treatment for macular degeneration, targets vascular endothelial growth factor A, a protein involved in the growth of blood vessels.